Brian Hess
Impact in
-
- Lymphoma Diagnosis and Treatment
- Oncology top 10%
- CAR-T cell therapy research
- HER2/EGFR in Cancer Research
Papers in
- Oncology 33
- CAR-T cell therapy research 24
-
- Lymphoma Diagnosis and Treatment 26
- Co-authors
- Carmelo Carlo‐Stella (12 shared papers)Pier Luigi Zinzani (14 shared papers)Melhem Solh (15 shared papers)Brad S. Kahl (13 shared papers)John Radford (12 shared papers)Weiyun Z. Ai (11 shared papers)Paolo F. Caimi (11 shared papers)Kirit M. Ardeshna (13 shared papers)
- Journals
- Blood (19 papers)Journal of Clinical Oncology (6 papers)Hematological Oncology (5 papers)Blood Advances (3 papers)Haematologica (1 paper)
- Partner nations
- United StatesUnited KingdomItaly
In The Last Decade
Brian Hess
48 papers receiving 590 citations
Brian Hess's Hit Papers
Peers
Comparison fields: 5 of 42
- Pathology and Forensic Medicine 354
- Oncology 452
- Genetics 96
- Dermatology 71
- Immunology 122
Countries citing papers authored by Brian Hess
This map shows the geographic impact of Brian Hess's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brian Hess with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brian Hess more than expected).
Fields of papers citing papers by Brian Hess
This network shows the impact of papers produced by Brian Hess. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brian Hess. The network helps show where Brian Hess may publish in the future.
Co-authors
The 25 scholars most cited alongside Brian Hess, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 53 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial Hit paper breakdown → | 2021 | 264 |
| 2 | 2010 | 32 | |
| 3 | 2022 | 28 | |
| 4 | 2022 | 25 | |
| 5 | 2023 | 23 | |
| 6 | 2018 | 22 | |
| 7 | 2019 | 22 | |
| 8 | 2020 | 19 | |
| 9 | 2023 | 16 | |
| 10 | 2020 | 14 | |
| 11 | 2020 | 13 | |
| 12 | 2023 | 9 | |
| 13 | 2021 | 8 | |
| 14 | 2015 | 6 | |
| 15 | 2018 | 6 | |
| 16 | 2018 | 6 | |
| 17 | 2019 | 6 | |
| 18 | 2021 | 6 | |
| 19 | 2023 | 5 | |
| 20 | 2010 | 5 |
About Brian Hess
Brian Hess is a scholar working on Oncology, Pathology and Forensic Medicine, Genetics, Dermatology and Immunology, having authored 53 papers that have together received 597 indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (26 papers), CAR-T cell therapy research (24 papers), Chronic Lymphocytic Leukemia Research (15 papers), Cutaneous lymphoproliferative disorders research (8 papers), Monoclonal and Polyclonal Antibodies Research (6 papers), Synthesis and pharmacology of benzodiazepine derivatives (5 papers), Protein Degradation and Inhibitors (4 papers) and Immune Cell Function and Interaction (4 papers). The work is most often cited by research in Pathology and Forensic Medicine (354 citations), Oncology (452 citations), Genetics (96 citations), Dermatology (71 citations) and Immunology (122 citations). Brian Hess has collaborated with scholars based in United States, United Kingdom and Italy. Frequent co-authors include Carmelo Carlo‐Stella, Pier Luigi Zinzani, Melhem Solh, Brad S. Kahl, John Radford, Weiyun Z. Ai, Paolo F. Caimi, Kirit M. Ardeshna, Anastasios Stathis and Juan Pablo Alderuccio. Their work appears in journals such as Blood, Journal of Clinical Oncology, Hematological Oncology, Blood Advances and Haematologica.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.